p21's Dual Role in Cancer Depends on Subcellular Localization and Post-Translational Modifications

The cell cycle inhibitor p21 (Cip1/Waf1/Sdi1) is a critical regulator of cell proliferation, often induced by p53 to arrest the cell cycle upon DNA damage, thereby preventing oncogenesis. However, p21's role in cancer is paradoxically dual, sometimes promoting tumor growth despite its known anti-proliferative functions. This ambiguity highlights a significant gap in understanding how a single protein can exert such opposing effects on cell fate, necessitating a deeper look into its regulatory mechanisms beyond simple presence.

This review article synthesized existing literature to explore the dichotomous functions of p21 in cancer. The authors focused on how the intracellular localization of p21—specifically its nuclear versus cytoplasmic presence—dictates its pro- or anti-cancerogenic activities. They also examined the role of post-translational modifications (PTMs), primarily phosphorylations, in regulating p21's subcellular compartmentalization and, consequently, its ultimate impact on cell fate, including cell death or survival.

The review elucidated that p21's anti-cancerogenic activities are intrinsically linked to its nuclear localization, where it functions as a classic cyclin-dependent kinase (CDK) inhibitor, arresting the cell cycle and preventing uncontrolled proliferation. Conversely, cytoplasmic p21 is associated with pro-cancerogenic effects, potentially by inhibiting apoptosis or promoting cell survival pathways independently of its CDK-inhibitory role. The authors highlighted that specific post-translational modifications, particularly phosphorylations, are key determinants of p21's intracellular trafficking and localization. These modifications act as molecular switches, directing p21 to either the nucleus or the cytoplasm, thereby dictating its functional outcome in the context of oncogenesis. This compartment-specific regulation explains the long-observed controversial actions of p21.

Nuclear p21 primarily acts as a tumor suppressor by inhibiting cyclin-CDK complexes, while cytoplasmic p21 can promote tumorigenesis through alternative mechanisms.